Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

172.19 +2.60 (+1.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals ↗

May 27, 2022

The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel...

Via Benzinga

Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating ↗

May 17, 2022

Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Via Investor's Business Daily

Jazz Pharmaceuticals's Return On Capital Employed Insights ↗

May 17, 2022

Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between...

Via Benzinga

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval? ↗

May 11, 2022

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.

Via Benzinga

Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next? ↗

May 09, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S.

Via Benzinga

Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate ↗

May 05, 2022

Via Benzinga

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma ↗

April 07, 2022

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

May 05, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗

May 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY ↗

May 05, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Via Benzinga

Jazz Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End ↗

April 20, 2022

Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday.

Via Benzinga

Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent ↗

April 19, 2022

The company agreed to the FDA's post-marketing requirements for a depression drug.

Via Investor's Business Daily

Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal ↗

April 13, 2022

Via Benzinga

Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies ↗

April 11, 2022

Syros Pharmaceuticals Inc (NASDAQ: SYRS)

Via Benzinga

Expert Ratings For Jazz Pharmaceuticals ↗

April 06, 2022

Over the past 3 months, 4 analysts have published their opinion on Jazz Pharmaceuticals (NASDAQ:JAZZ) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

April 06, 2022

Raymond James reduced the price target on Intercontinental Exchange, Inc. (NYSE: ICE) from $161 to $157. Intercontinental Exchange shares rose 0.2% to $130.79 in pre-market trading.

Via Benzinga

Why Axsome Therapeutics Stock Is Trading Higher ↗

March 28, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) is trading higher Monday morning after the company announced it will acquire Sunosi from Jazz Therapeutics PLC (NASDAQ: JAZZ).

Via Benzinga

Axsome Acquires Sleep Disorder Drug From Jazz Pharma, Expanding Its Neuroscience Portfolio ↗

March 28, 2022

Axsome Therapeutics Inc (NASDAQ: AXSM) has

Via Benzinga

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗

March 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Jazz Pharmaceuticals's Return On Capital Employed Insights ↗

March 03, 2022

According to data from Benzinga Pro, during Q4, Jazz Pharmaceuticals's (NASDAQ:JAZZ) reported sales totaled $896.73 million. Despite a 33.09% increase in earnings, the company...

Via Benzinga

Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma ↗

March 03, 2022

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C...

Via Benzinga

Expert Ratings For Jazz Pharmaceuticals ↗

March 02, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results ↗

March 01, 2022

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma...

Via Benzinga

Jazz Pharmaceuticals: Q4 Earnings Insights ↗

March 01, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today